Co-Host: Kelvin Moses, MD
At the conclusion of these activities, participants will be able to:
1. Identify the active agents and their mechanism of action in the management of metastatic HSPC.
2. Describe the risks and benefits of treatment for metastatic HSPC.
CME Available: auau.auanet.org/node/26063
This educational series is supported by independent educational grants from:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Genomic Health
Merck
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma
